All news

Nanolek plans to launch CoviVac vaccine production in November — company

"We will try to reach the volume of about three million [doses] a month, as we initially announced," deputy general director Maxim Stetsyuk noted

GELENDZHIK, October 5. /TASS/. The Russian biopharmaceutical company Nanolek plans to start production of the CoviVac vaccine against the coronavirus in November, Maxim Stetsyuk, the company’s deputy general director and head of its vaccine division, told TASS.

He added that the company will try to reach a production volume of three million doses per month.

"We plan to start producing CoviVac in November. We will try to reach the volume of about three million [doses] a month, as we initially announced. Of course, it is unlikely that we will be able to gain such capacity in November-December, but we will try," he said on the sidelines of the Biotechmed forum.

"Taking into account the complexity of pharmaceutical production, we may encounter some difficulties," he explained.

Earlier, the company said that it planned to obtain a registration certificate for the production of CoviVac by the end of autumn. The company added that it would be able to fully meet the domestic demand for this vaccine in 2022.

Nanolek is a Russian biopharmaceutical company with its own full-cycle production according to GMP standards. It specializes in the production of import-substituting and innovative medicines, both of its own design and those developed in cooperation with international partners.

CoviVac vaccine

On February 19, 2021, the Russian Health Ministry registered the whole-virion CoviVac vaccine, developed by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences. This type of jab uses either artificially weakened viruses that cannot cause disease, or viruses that have already been killed (inactivated).